Upgrade to SI Premium - Free Trial

Chemours (CC) PT Lowered to $19 at UBS

August 2, 2019 7:07 AM

UBS analyst John Roberts lowered the price target on Chemours (NYSE: CC) to $19.00 (from $21.00) while maintaining a Neutral rating.

Categories

Analyst PT Change

Next Articles